Zeria Pharmaceutical Co., Ltd. (TSE: 4559)
Health Care · Pharmaceuticals · JP
¥2,153.00
+1.99% today · +3.9% 1Y
Zeria Pharmaceutical Co., Ltd. (TSE: 4559) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $596.96M and employs 1,748 people.
Over the last twelve months the share price has gained 3.9%, trading between 1.88K and 2.43K.
Tweenvest scores Zeria Pharmaceutical Co., Ltd. across four factors: quality 74/100, value 73/100, growth 41/100, dividend 49/100. Its strongest factor is quality.
4559 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $596.96M
- Revenue (TTM)
- $560.57M
- P/E
- 11.53
- EPS
- 186.70
- Dividend yield
- 2.32%
- Beta (5Y)
- 0.06
- 52-week high
- ¥2,434.00
- 52-week low
- ¥1,878.00
- Avg volume (3M)
- —
- Shares outstanding
- 44.08M
- Employees
- 1,748
- Next earnings
- —
About Zeria Pharmaceutical Co., Ltd.
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn’s disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.
- ISIN
- JP3428850006
- Founded
- 1955
- Listed since
- Jan 1, 2001
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.